Clinical Trials Logo

Clinical Trial Summary

The purpose of this study is to compare the efficacy of BHV-3000 (rimegepant) versus placebo in subjects with Acute Migraines


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT03235479
Study type Interventional
Source Pfizer
Contact
Status Completed
Phase Phase 3
Start date July 18, 2017
Completion date January 26, 2018

See also
  Status Clinical Trial Phase
Completed NCT02848326 - Efficacy, Safety, and Tolerability of Multiple Dosing Regimens of Oral Atogepant (AGN-241689) in Episodic Migraine Prevention Phase 2/Phase 3
Completed NCT02873221 - An Extension Study to Evaluate the Long-Term Safety and Tolerability of Ubrogepant in the Treatment of Migraine Phase 3
Completed NCT03237845 - Safety and Efficacy in Adult Subjects With Acute Migraines Phase 3
Completed NCT02828020 - Efficacy, Safety, and Tolerability Study of Oral Ubrogepant in the Acute Treatment of Migraine Phase 3
Completed NCT03461757 - Trial in Adult Subjects With Acute Migraines Phase 3
Completed NCT03266588 - Open Label Safety Study in Acute Treatment of Migraine Phase 2/Phase 3
Completed NCT02867709 - Efficacy, Safety, and Tolerability of Oral Ubrogepant in the Acute Treatment of Migraine Phase 3